Last reviewed · How we verify

Acute myeloblastic leukemia — Treatment Landscape & Competitive Intelligence

Acute myeloblastic leukemia (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute myeloblastic leukemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Doxorubicin Hydrochloride Doxorubicin Hydrochloride Pfizer Inc. Anthracycline topoisomerase inhibitor DNA topoisomerase II, nucleotide bases

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer Inc. · 1 drug in Acute myeloblastic leukemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute myeloblastic leukemia:

Cite this brief

Drug Landscape (2026). Acute myeloblastic leukemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-myeloblastic-leukemia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing